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Fumihiko Attempts to treat congenital protein deficiencies using bone marrowderived cells have been reported. These efforts have been based on the concepts of stem cell plasticity. However, it is considered more difficult to restore structural proteins than to restore secretory enzymes. This study aims to clarify whether bone marrow transplantation (BMT) treatment can rescue epidermolysis bullosa (EB) caused by defects in keratinocyte structural proteins. BMT treatment of adult collagen XVII (Col17) knockout mice induced donor-derived keratinocytes and Col17 expression associated with the recovery of hemidesmosomal structure and better skin manifestations, as well improving the survival rate. Both hematopoietic and mesenchymal stem cells have the potential to produce Col17 in the BMT treatment model. Furthermore, human cord blood CD34 + cells also differentiated into keratinocytes and expressed human skin component proteins in transplanted immunocompromised (NOD/SCID/γ c null ) mice. The current conventional BMT techniques have significant potential as a systemic therapeutic approach for the treatment of human EB. Although some papers have reported that "transdifferentiation" of circulating hematopoietic stem cells is an extremely rare event (9) , previous reports have shown that expression of systemic enzymes and certain secreted factors can be recovered after bone marrow transplantation (BMT) (10) .
Epidermolysis bullosa (EB) comprises a group of genodermatoses, which are caused by mutations in one of the genes encoding anchor proteins that stabilize the basement membrane zone (BMZ) of the skin and mucous membranes (11) . Collagen XVII (COL17) is a transmembrane component of hemidesmosomal adhesion structures anchoring cells to the BMZ. COL17 is the gene underlying non-Herlitz junctional EB in humans, a disorder that causes severe skin fragility, hair loss, growth retardation, and enamel hypoplasia (11) . There is no effective treatment for EB other than palliative care. Gene-treated cultured autografting, reported by Mavilio et al. (12) , is a promising therapeutic approach for junctional EB. However, its effects are limited to the area of application, in addition to the ethical and safety problems of using viruses for gene correction, even if the recent development of lentiviral vectors with favorable safety might be able to avoid the risks of gene augmentation with traditional retroviral constructs (13) . Therefore, systemic and ethically safer therapies would be preferable.
Previous work reported that cells of human or murine origin do home to the skin, such as in graft-versus-host disease in humans (14) and epithelial progenitors in murine bone marrow (15) . Our group reported that donor-derived keratinocytes could be identified at wound sites in a BMT model (16) . This suggests that BMT techniques have the potential to provide functional keratinocytes over the entire skin surface. The current study investigates whether BM-derived cells can differentiate into donor-derived keratinocytes and subsequently produce detectable COL17 protein after BMT, with the ultimate goal of improving the clinical phenotype and contributing to long-term survival in our model mice.
Results

Donor BM-Derived Cells Express Col17 Protein in the BMZ in Recipient
Mouse Skin. To investigate whether BM-derived keratinocytes can produce skin component proteins, we transplanted BM-derived cells of C57BL/6 mice expressing human COL17 (hCOL17) driven by the keratin 14 promoter (COL17 m+/+,h+ ) into wildtype C57BL/6 mice in the first set of experiments. Detection of hCOL17 protein in the epithelized recipient skin would indicate that donor BM-derived cells had differentiated into keratinocytes. Immunohistochemical analysis revealed hCOL17 protein expression in the BMZ within the wounded area for four out of the eight BMT-treated C57BL/6 mice (Fig. 1A) . RT-PCR analysis also showed evidence of hCOL17 mRNA expression in five out of the eight treated mice (Fig. 1B) .
We subsequently performed another BMT experiment: BMderived cells from GFP + Tg mice were transplanted into COL17-humanized (COL17 m−/−,h+ ) mice (Fig. S1) (17) . In this experimental pattern, BM-derived cells that differentiated into keratinocytes in the host mice were found to have the potential to produce mCol17 protein. BM-derived nonhematopoietic cells expressing GFP + CD45 − were sparsely observed, accounting for 1.83 ± 0.82% (n = 5) of the basal layer cells (Fig. 1C) . Aggregated GFP + cytokeratin + cells were also found in the basal cell layer (Fig. 1D) . Epithelized skin areas in this experiment demonstrated mCol17 protein expression, although unwounded areas of the transplanted COL17 m−/−,h+ mice failed to express that protein (Fig. 1E ). This mCol17 expression lasted at least 9 mo after wound formation in two out of the three investigated mice (Fig. S2) . RT-PCR analysis also revealed the expression of mCol17 mRNA in epithelized skin from four of the five transplanted mice, indicating that the BM-derived epidermal cells were able to express active mCol17 (Fig. 1F ). ) as a result of homozygous ablation of the Col17 gene (17) . Unlike EB model mice reported by other researchers, our model has allowed us to obtain adult COL17 m−/− mice that can be used for various therapeutic strategies (Fig. S3) . We speculated that mCol17 protein would be reintroduced by administering BM-derived cells from BMT treatments into COL17 m−/− EB model mice. We transplanted BM cells of the GFP + Tg mice into the COL17 m−/− mice. All of the mice obtained hematopoietic chimeras (710. ± 4.0%, n = 21). Immunohistochemical analysis revealed sporadic GFP + cells in the basal cell layer of the epidermis, accounting for 1.08 ± 0.39% of the basal cells (n = 11). GFP + CD45 − cells including cytokeratin + epidermal keratinocytes were also found (0.26% ± 0.08% of basal cells) ( Fig. 2A and Fig. S4 ). Linear deposition of mCol17 along the BMZ, and GFP + cells above the mCol17 staining were observed, accounting for 14.7 ± 3.0% (n = 11) of the epithelized area (Fig. 2B) . Also, a 180-kDa mCol17 protein was detected in Western blotting (Fig. 2C ). One out of three mice showed positive mCol17 immunohistochemically in unwounded skin from the back (Fig. S5A ). Eight out of nine BMT-treated mice showed positive mCol17 mRNA in the epithelized skin tissues. Compared with unwounded skin, epithelized areas of skin tended to show mCol17 mRNA expression more frequently (Fig. S5B) . We also performed RT-PCR analysis on the epithelized areas of BMT-treated COL17 m−/− mice from the epidermis and the dermis by detaching each side enzymatically; this revealed positivity only on the epidermal side ( Fig.  2D ). Next, we sorted GFP + cells from the single-cell suspension of epithelized epidermal cells. A portion of the suspended epidermal cells showed GFP (1.24 ± 0.12%, n = 4; Fig. S6 ), and mRNA expression specific to epidermal keratinocytes was detected from the extract of the GFP + epidermal cells. These cells also expressed mCol17 mRNA in three out of the four investigated mice (Fig. 2E ). To rule out the possibility that cell fusion was occurring between BM cells and original keratinocytes in the COL17 m−/− mice, we performed FISH analysis in a sex-mismatched BMT model. Several fused cells with XXXY chromosomes in the same nucleus were found in the deep dermis of the epithelized skin (Fig. 2F) . Conversely, no fused cells were found in the epidermis of the samples we investigated, whereas 50 of 1,793 basal cells (2.79%) showed donor-derived XY chromosomes. To investigate the restoration of COL17 expression and its effect on restoring normal BMZ structure, we performed electron microscopic analysis. In the BMTtreated COL17 m−/− mice, a portion of the basal cells had mature hemidesmosomes (Fig. 2G) . The average thickness of outer plaques of hemidesmosomes was 79.7 ± 3.2 nm in the wild-type mice, 45.1 ± 1.4 nm in the untreated COL17 m−/− mice, and 61.1 ± 1.9 nm in the BMT-treated COL17 m−/− mice (P < 0.01). To exclude the nonspecific effects of bone marrow infusion, a mixture of lineage + differentiated GFP + BM cells and lineage − COL17 m−/− BM cells was transplanted into the COL17 m−/− mice. No Col17 expression of mRNA and protein were detected in the epithelized skin (n = 3).
Col17 Knockout Mice Exhibit Less Severe Clinical Manifestations and
Better Survival Prognosis After BMT than Untreated Mice. To investigate the change in vulnerability to friction in skin that resulted from the restoration of Col17, we rubbed the back of each mouse (18) . The BMT-treated mice (n = 6) significantly showed formation of smaller erosions compared with the untreated mice (n = 4) (Fig. 3A) . Although our COL17 m−/− mice survived longer than previously reported EB models, only 12.5% of the mice survived to 1 mo, approximately half of which died within the following 3 mo (17) . Surprisingly BMT-treated recipients (Fig. 3B) . The BMT technique brought significant therapeutic benefits to the COL17 m−/− EB model mice. The untreated adult COL17 m−/− EB model mice showed spontaneous erosions, ulcers, nail deformity, hair loss, and hair graying similar to those seen in human junctional EB patients lacking COL17 (17). The erosions were especially severe in the genital regions (Fig. 3C) . The BMT-treated COL17 m−/− mice showed improvements to clinical manifestations, with fewer spontaneous erosions than for the untreated COL17 m−/− mice and BMT-control COL17 m−/− mice (COL17 m−/− mice as donors). The improvements were particularly marked in the genital regions (Fig. S7) . (Fig. 4A) . Four weeks after BMT, we confirmed partial chimerism (37.0 ± 13.7%, n = 5) of GFP in peripheral blood of BMTtreated mice with GFP + HSCs (HSC-BMT mice), whereas no GFP + peripheral blood cells were detected in BMT-treated mice with GFP + MSCs (MSC-BMT mice, n = 4) (Fig. S8) . Immunohistochemical analysis revealed sparse GFP + cytokeratin + keratinocytes in the skin of the HSC-and MSC-BMT mice (Fig.  4B ). Both HSCs and MSCs were found to have the potential to produce mCol17 as observed immunohistochemically; three out of five HSC-BMT mice and two out of four MSC-BMT mice showed positive mCol17 (Fig. 4C) . RT-PCR analysis also demonstrated the expression of mCol17 in both the HSC-BMT model (three out of five mice) and the MSC-BMT model (two out of four mice) (Fig. 4D) . HSC-BMT mice showed better clinical manifestations than untreated COL17 m−/− mice, whereas mice of the MSC-BMT model had a tendency to show more severe perianal erosions and hair loss (Fig. 4E) .
Transplanted Human Cord Blood CD34
+ Cells Obtain a KeratinocyteLike Phenotype and Produce Epidermal Component Proteins. Toward clinical applications of stem cell transplantation therapies in human EB patients, we investigated whether the human hematopoietic stem cells have the ability to supply structural proteins in the BMZ of the skin. A human-to-mouse xenogeneic transplantation model was investigated using NOD/SCID/γ c null (NOG) mice (19) . Using immunohistochemistry, human cells that expressed human leukocyte antigen (HLA)-ABC could be seen, and pancytokeratin-positive cells were sporadically costained (0.39 ± 0.15% of the basal cells, n = 4) (Fig. 5 A and B) , which indicates that these cells are donor cellderived keratinocytes. In addition, sparse and intermittent hCOL17 was detected along the BMZ in two of seven treated mice (Fig. 5C) . RT-PCR analysis surprisingly showed mRNA expression of several components of the normal human BMZ other than hCOL17 (detected in six of seven treated mice), including BPAG1 (four of seven), plectin (four of seven), α6 integrin (five of seven), laminin β3 (two of seven), and laminin γ2 (one out of seven) (Fig. 5D ).
Discussion
Junctional EB is caused by mutations in the genes coding for structural proteins anchoring the skin to the underlying basal lamina and dermis. Recently, various treatments were reported to restore the deficient proteins. These approaches fall mainly into three strategies: gene therapy (20) (21) (22) (23) (24) , protein therapy (21, 25, 26) , and cell therapy. Cell therapies using fibroblasts have been attempted for recessive dystrophic EB (RDEB) model mice and human patients, both of which lack collagen VII. Intradermal fibroblast cell therapy was reported for RDEB model mice (18) and RDEB human patients (27) . These approaches may prove to be fundamental treatments for EB. However, their effects are transient and occur only where the genes, proteins, or cells are introduced; they may cause rejection and such genecorrection approaches still raise questions of ethics and safety.
Woodley et al. (28) recently reported that i.v. injection of human fibroblasts induces systemic production of human collagen VII in immunodeficient mice; however, major ethical and safety problems remain in human patients. BMT, an established, widely used medical technique for hematologic malignancies, has recently been attempted for severe hereditary genetic disorders. Hobbs et al. (29) first reported the efficacy of BMT for treatment of Hurler's syndrome. Later hematopoietic stem cell transplantation proved effective in other mucopolysaccharidoses (30) (31) (32) (33) . More recently, Sampaolesi et al. (34) reported on the potential of stem cell therapy for the treatment of Duchene muscular dystrophy. These experiments indicate that stem cell therapies including BMT are promising candidates for several congenital genetic disorders. BMT techniques have three advantages over previous cell therapies: (i) systemic and long-lasting effects can be expected from the circulating BM-derived cells, (ii) conventional BMT techniques can be used in clinical applications, and therefore (iii) fewer ethical problems arise from the treatment.
Recently Tolar et al. (35) reported that hematopoietic stem cells contributed to life prolongation in RDEB neonatal mice. Chino et al. (36) reported that treatment of embryonic BMT in RDEB mice induced the expression of donor-derived fibroblasts and type VII collagen. These reports investigated neonatal or embryonic mice and focused on type VII collagen, which is produced mainly by dermal fibroblasts. In this study we show the potential of BMT therapies in adult mice with cutaneous congenital disorders caused by deficiencies of transmembrane proteins such as COL17, which is produced mainly by keratinocytes.
As to the origin of the BM-derived cells that differentiated into epidermal cells, Tolar et al. reported that only CD150 + CD48
− HSCs contributed to the amelioration of RDEB mice; nevertheless, MSCs abundantly expressed type VII collagen mRNA (35) . Conversely, we and other groups have reported that MSCs also have the potential to differentiate into keratinocytes (37, 38) . Our experiments have shown that both HSCs and MSCs have the potential to produce Col17. However, a BMT model with infusion of enriched MSCs tended to induce more severe clinical manifestations. One hypothesis is that the infused MSCs in BMT reside so shortly that long-term effects, such as clinical improvement, might not occur (39, 40) . We demonstrated that human cord blood CD34 + HSCs are able to differentiate into keratinocytes in vivo. Although further investigation is needed, we suggest that the difference between the benefits of MSC and HSC transplantations owes to the lack of a long-term, renewable circulating source of Col17-producing cells induced by donor hematopoiesis. From these findings we conclude that both HSCs and MSCs contributed to the production of Col17, although HSCs played more a significant role in clinical improvement in our EB model mice.
Recently Kopp et al. (41) performed BMT and subsequent skin transplantation in one Herlitz-junctional EB infant but unfortunately the child died. They performed normal conditioning treatments similar to those used in hematological malignancies, but the treatments might be too strong for EB patients. Indeed, in our EB model mice, we had to reduce the irradiation dose before BMT to avoid erosions. This report is highly suggestive toward determining conditioning regimens.
In conclusion, we confirmed the reexpression of the previously deficient anchoring protein Col17, better clinical appearance, and longer life expectancy after BMT in our junctional EB model mice. Furthermore we demonstrated that human HSCs can contribute to the regeneration of wounded skin, producing structural proteins in the BMZ. Current conventional hematopoietic stem cell transplantation will lead to treatments for severe forms of EB or even other congenital skin disorders involving epidermal structural proteins.
Materials and Methods
Bone Marrow Transplantation. Recipient adult mice were irradiated with a lethal dose of X-rays at 9 Gy (C57BL/6 and COL17 m−/−,h+ mice) or 6 Gy (in COL17 m−/− mice), 12 h before infusions. The 9-Gy irradiation resulted in severe erosions and hair loss within 4 wk after BMT to COL17 m−/− mice. Approximately 3.0-6.0 × 10 6 murine BM-derived cells in 400 μL PBS were injected through the mouse tail vein.
Human Cord Blood Stem Cell Transplantation. Recipient adult NOG mice were irradiated with a sublethal dose of X-rays at 2.5 Gy. Twelve hours later, approximately 1.0-2.5 × 10 5 human CD34 + cells in 400 μL PBS were injected through the mouse tail vein. Hematopoietic reconstitution was evaluated in peripheral blood mononuclear cells 12 wk after transplantation. RT-PCR Analyses. For RT-PCR, total RNA from tissues and cells was extracted using Isogen (Nippon Gene) and 200 ng of total RNA was used for cDNA synthesis in SuperScript II reverse transcriptase according to the manufacturer's instructions (Invitrogen). RT-PCR analysis of mRNA was performed in a thermocycler (GeneAmp PCR system 9600; Perkin-Elmer). The primers specific for protein sequences are summarized in Table S1 . The PCR protocol for these genes included 35 cycles of amplification (denaturing at 94°C for 1 min, annealing for 1 min, elongation at 72°C for 1 min). Aliquots from each amplification reaction were analyzed by electrophoresis in 2% acrylamide-Tris-borate gels. Gel images were acquired and processed by an image analyzer (LAS-4000UVmini; Fujifilm).
Western Blotting. Protein lysates from epidermal tissues were subjected to SDS/PAGE and electrophoretically transferred onto a nitrocellulose membrane. The membranes were blocked with 1% nonfat dry milk in PBS, probed with rat monoclonal antibodies against mCol17 (KT4.2, 1:80,000), and then allowed to react with goat anti-rat IgG antibody coupled with HRP (1:1,000; Southern Biotech). For loading control, we used mouse anti-β-actin antibody (1:1,000; Sigma-Aldrich) and HRP-conjugated goat anti-mouse IgG (1:1,000; Southern Biotech). The resultant immune complexes were visualized using a chemiluminescent detection system (LumiGLO; Cell Signaling Technology) and processed by an image analyzer (LAS-4000UVmini).
Ultrastructural Observations. Skin biopsy samples of two mice each from GFP + Tg mice, untreated COL17 m−/− mice, and BMT-treated COL17 m−/− mice were fixed in 5% glutaraldehyde solution, postfixed in 1% osmium tetroxide, dehydrated, and embedded in Epon 812. The samples were sectioned at 1-μm thickness for light microscopy and thin-sectioned at 70-nm thickness for electron microscopy. The thin sections were stained with uranyl acetate and lead citrate and examined under a transmission electron microscope (H-7100; Hitachi High-Technologies).
Clinical Evaluation of COL17 m−/− Mice. After bone marrow transplantation, the clinical severity of the BMT-treated COL17 m−/− mice, such as spontaneous erosions and blistering, was evaluated and compared with that of the untreated COL17 m−/− mice and BMT-control mice whose donors were COL17 m−/− mice. The perioral area and circumanal area tend to be naturally predisposed to erosion. We investigated the clinical severity by measuring the share of each affected area as a percent of its entire region. These were assessed by two independent assessors viewing the same clinical images. In addition we compared the vital prognosis after BMT (35 d after birth) among BMT-treated mice (n = 20), untreated COL17 m−/− mice (n = 17), and BMT-control mice (n = 6).
Mechanical Rubber Stress Test. The epithelized dorsal skin areas of 1 cm 2 after erosion were marked with a pen and exposed to a mechanical rubber stress test as previously reported (18) . The skin was gently stretched, and mechanical shearing forces were applied by the same investigator repeatedly (25 times) as intense, unidirectional rubbing with a pencil eraser. After 20 min, skin specimens were excised and processed for histopathological analysis. Also, we measured the total areas of erosion by ImageJ software (42) .
Statistical Analyses. Mann-Whitney U test for nonparametric data, KaplanMeier analysis for survival curves, and log-rank test for survival evaluation were performed using Excel 2003 (Microsoft) with the add-in software Statcel2 (OMS) (43) . For comparison of more than two groups, data were analyzed by KruskalWallis test followed by Scheffe's F test. Results were expressed as mean ± SE.
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